• Skip to primary navigation
  • Skip to content
  • Skip to footer
Gynesonics

Gynesonics

Advancing technology. Improving women's lives.

  • Our Company
    • About Us
    • Careers
    • Compliance
  • Our People
    • Management
    • Board of Directors
    • Investors
  • Our Technology
    • The Sonata System
    • Indications and Safety
    • Instructions for Use
    • Request for Medical or Scientific Information
  • Our News
    • Press Releases
    • In the News
    • Publications
    • 2022 Events
  • Contact Us

Press Releases

Apr 8, 2021

Gynesonics Announces Publication of Clinical Study Analysis Demonstrating Effectiveness of the Sonata System in Treating Submucous and Large Symptomatic Uterine Fibroids

The analysis shows that fibroids, which are often treated by hysteroscopic resection or morcellation, can be effectively treated with the Sonata® System, the only incision-free, transcervical procedure that can treat most submucous, intramural, subserous, transmural and large fibroids REDWOOD CITY, CA, April 8, 2021 – Gynesonics®, a women’s healthcare company focused on the development of […]

Mar 31, 2021

Gynesonics Appoints Susan Stimson To Its Board of Directors

Executive with Extensive Commercialization Experience to Provide Key Insights on Global Launch Strategies Redwood City, CA, March 18, 2021– Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Susan Stimson has been appointed as an independent member to the company’s Board […]

Mar 15, 2021

Gynesonics Announces Positive Payer Coverage Issued by Health Care Service Corporation (HCSC) for the Sonata Treatment

HCSC is the largest customer-owned health insurer in the United States, operating Blue Cross and Blue Shield® Plans in Illinois, Montana, New Mexico, Oklahoma, and Texas Redwood City, CA, March 15, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Health Care […]

Mar 9, 2021

Gynesonics Announces Centers for Medicare and Medicaid Services Final Rule Approves Ambulatory Surgery Centers as a Site of Service for Transcervical Uterine Fibroid Ablation with Device Intensive Designation

2021 Ruling Also Increases Hospital Outpatient Payment for the Associated Ambulatory Payment Classification That Covers the Sonata Treatment Redwood City, CA, March 9, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that The Centers for Medicare and Medicaid Services (CMS) has included […]

Jan 21, 2021

Gynesonics Announces that Detroit Medical Center Huron Valley-Sinai Hospital has Introduced Sonata, a New Innovative, Incision-Free Treatment for Symptomatic Uterine Fibroids

Detroit Medical Center’s Danny Benjamin, M.D., FACOG, Chief of Obstetrics and Gynecology at DMC Huron Valley-Sinai Hospital, is the first to provide the uterus-preserving, outpatient treatment option to women in Michigan Redwood City, CA, January 21, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, […]

Dec 21, 2020

Sonata, a New Innovative, Incision-Free Treatment for Symptomatic Uterine Fibroids, has been Introduced in the MedStar Health System

MedStar Health is the first health system to provide Sonata, an incision-free, uterus-preserving, outpatient treatment option for women in the Maryland and Washington D.C. area Redwood City, CA – December 21, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that MedStar Health, […]

Oct 27, 2020

Sonata, A New Innovative, Incision-Free Procedure To Treat Symptomatic Uterine Fibroids, Expands in New York Area

Treatment provides women with a uterus-preserving, incision-free, outpatient option with significant symptom relief and fast recovery Redwood City, October  27, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today continued Sonata expansion in the New York area, including NewYork-Presbyterian/Columbia University Irving Medical Center […]

Oct 13, 2020

Gynesonics Announces Publication of Long Term Three-Year Results of the SONATA FDA IDE Pivotal Trial

Outcomes Demonstrate Significant and Sustained Symptom Relief, High Patient Satisfaction,  Improved Quality of Life and Low Reintervention Rates Redwood City, CA, October 13, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced the publication of its peer reviewed journal article, “Three-Year Results of the […]

Sep 22, 2020

Gynesonics Introduces Sonata in Prominent New York City Fibroid Center

Sonata System Offers Innovative Incision-Free Fibroid Treatment Option For Women Suffering from Symptomatic Uterine Fibroids Redwood City, Calif., September 22, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today its Sonata® System will be offered by surgeons at Mount Sinai Health System to […]

Sep 3, 2020

Gynesonics Announces Brigham and Women’s Faulkner Hospital Becomes the First in Massachusetts to Offer Innovative New Procedure to Treat Symptomatic Uterine Fibroids

Sonata Treatment provides patients with an incision-free, outpatient option with exceptional results and fast recovery Redwood City, Calif. – September 3, 2020 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Brigham and Women’s Faulkner Hospital is the first provider in Massachusetts to […]

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next »

Footer

  • Privacy Policy
  • Terms of Use
  • Patents
  • Safety Information

© Copyright 2023 Gynesonics · All Rights Reserved · WS 05198 Rev. J

This website uses cookies to provide you with the best browsing experience.

Find out more or adjust your settings.

Gynesonics
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Show details
Name Provider Purpose Expiration
moove_gdpr_popup Gynesonics via Moove GDPR Plugin This is used to save your cookie settings for this website. 12 months
__cf_bm Cloudflare The __cf_bm cookie is a cookie necessary to support Cloudflare Bot Management. As part of their bot management service, this cookie helps manage incoming traffic that matches criteria associated with bots. Cookie is set on websites using Cloudfare and it is related to rate limiting policies. less than 12m
Analytics Cookies

This website uses analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Show details
Name Provider Purpose Expiration
_ga, _gat, _gid, _ga_* Google Analytics These cookies enable analytics features in our suite (e.g., distinguish users, remember traffic information, and determine the start and end of a session). They are set for analytics measures on our website. We can take a timestamp of your website visit, track the source (e.g. search engine) you used to access our website, and the number of times you visit our website. 1-12 months
_gcl_au, _gat_gtag_UA_* Google Tag Manager These cookies helps us to enable functional requests on our website, such as the communications between our website and resources such as style, fonts, and images. As a cookie related to our Tag Manager, it collects your interaction with our resources (e.g. clicks and views) to help us understand your behavior on our website as well as to improve our aggregated analysis from interactions and campaigns. 1-12 months